Veritas Genetics to Close Its Testing Operations in U.S.

By Joseph Burns

MAYBE CHARGING CONSUMERS THE LOW PRICE of $599 for a whole human genome sequence is not a winning financial strategy. That’s one possible reason why closely-watched Veritas Genetics of Cambridge, Mass., will stop operations in the United States. It was in July that Veritas annou…

Read More

---

Illumina to Pay $1.2 Billion to Acquire Pacific Biosciences

By Joseph Burns | From the Volume XXV No. 17 – December 3, 2018 Issue

IT’S AN ACQUISITION THAT BRINGS TOGETHER two different gene sequencing technologies into one firm. On Nov. 1, Illumina, Inc., announced an agreement to acquire Pacific Biosciences (PacBio) for $1.2 billion. This deal will bolster Illumina’s already-dominant posit…

Read More

---

April 3, 2017 Intelligence: Late Breaking Lab News

By Robert Michel | From the Volume XXIV No. 5 – April 3, 2017 Issue

For readers with a continuing interest in Theranos, the latest development at the troubled lab testing company involves an offer by Founder and CEO, Elizabeth Holmes, to its current shareholders. Various news outlets report that, for existing shareholders who agree not to sue Therano…

Read More

---

May 06, 2013 “Intelligence: Late Breaking Lab News”

By Robert Michel | From the Volume XX No. 6 – May 6, 2013 Issue

Much is happening in the anatomic pathology market in the Pacific Northwest. PAML, LLC (Spokane, Washington), and CellNetix (Seattle, Washington) finally executed the agreement whereby PAML made an equity investment in CellNetix. Now, the two lab companies will collaborate on developing…

Read More

---

How Digital Pathology Helps Pathologists Deliver Added Value

By Robert Michel | From the Volume XVIII No. 12 – September 6, 2011 Issue

“Pathologists have the opportunity to take on a new clinical role as the integrator of all that digital pathology information, in combination with the patient’s other clinical data collected from a wide variety of sources.” —Dirk G. Soenksen, M.S., M.B.A., Founder…

Read More

---

Our Top Ten Lab Stories Highlight Major Changes

By Robert Michel | From the Volume XVII No. 17 – December 6, 2010 Issue

CEO SUMMARY: What makes 2010 a watershed year for the laboratory testing industry is enactment of the 2,700-page Patient Protection and Affordable Care Act (PPACA). Even if parts of this bill are repealed, the remaining parts of the massive legislation will trigger major changes …

Read More

---

Whole Genome Sequencing: Is It Ready for Prime Time?

By Robert Michel | From the Volume XVII No. 16 – November 15, 2010 Issue

CEO Summary: Pathologists at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in a collaboration with GenomeQuest, Inc., will produce whole human genome sequences of patient tumors and other specimens. These whole genome sequences will be studied to learn what diagn…

Read More

---

“Primary-Care Pathology” One Goal at Beth Israel

By Robert Michel | From the Volume XVII No. 15 – October 25, 2010 Issue

CEO SUMMARY: In a pioneering collaboration, the pathology department at Beth Israel Deaconess Medical Center in Boston, Massachusetts, will work with GenomeQuest, Inc., to perform whole genome sequencing of tumor specimens. GenomeQuest will handle sequencing, assembly, and annota…

Read More

---

Clinical Labs and Whole Human Gene Sequencing

By R. Lewis Dark | From the Volume XVII No. 15 – October 25, 2010 Issue

CLINICAL LABORATORY ADMINISTRATORS AND SENIOR EXECUTIVES would be well advised to pay close attention to our lead story about the whole human genome sequence collaboration just announced by the pathology department at Beth Israel Deaconess Medical Center (BIDMC) and GenomeQue…

Read More

---

August 23, 2010 “Intelligence: Late Breaking Lab News”

By Robert Michel | From the Volume XVII No. 12 – August 23, 2010 Issue

With the goal of developing biomarkers useful in diagnosing a variety of cancers, Pathwork Diagnostics, Inc., and Novartis AG announced a research partnership on July 30. It is an early example of a collaboration between a diagnostics company and a pharmaceutical com…

Read More

---